Piper Jaffray Believes Halozyme (NASDAQ: HALO) Still Has Room to Grow

By Austin Angelo

Piper Jaffray analyst Charles Duncan reiterated a Buy rating on Halozyme (NASDAQ: HALO) on September 14 and set a price target of $26. The company’s shares closed on Friday at $16.25, close to its 52-week high of $16.65.

According to TipRanks.com, Duncan is a 4-star analyst with an average return of 3.8% and a 49.8% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Corcept Therapeutics Inc.

Currently, the analyst consensus on Halozyme is Strong Buy and the average price target is $19.50, representing a 20.0% upside.

In a report issued on September 15, Deutsche Bank also reiterated a Buy rating on the stock with a $20 price target.

The company has a one year high of $16.65 and a one year low of $8.18. Currently, Halozyme has an average volume of 1.21M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.